{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T20:11:46Z","timestamp":1788639106497,"version":"build-2803163510"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100030760","name":"Bayer in the USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030760","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13300-026-01899-9","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T08:23:22Z","timestamp":1784103802000},"page":"1251-1268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trajectory of Kidney Function in T1D over Time: A Scoping Review"],"prefix":"10.1007","volume":"17","author":[{"given":"Favian","family":"Co","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7046-0358","authenticated-orcid":false,"given":"Reid","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Katta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Aldworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Mares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihe","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Askin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navdeep","family":"Tangri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"Supplement_1","key":"1899_CR1","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.2337\/dc14-S081","volume":"37","author":"American Diabetes Association","year":"2014","unstructured":"American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Supplement_1):S81\u201390. https:\/\/doi.org\/10.2337\/dc14-S081.","journal-title":"Diabetes Care"},{"key":"1899_CR2","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jcjd.2017.10.003","volume":"42","author":"Z Punthakee","year":"2018","unstructured":"Punthakee Z, Goldenberg R, Katz P. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes. 2018;42:S10\u20135. https:\/\/doi.org\/10.1016\/j.jcjd.2017.10.003.","journal-title":"Can J Diabetes"},{"issue":"12","key":"1899_CR3","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s00125-021-05571-8","volume":"64","author":"A Green","year":"2017","unstructured":"Green A, Hede SM, Patterson CC, et\u00a0al. Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults. Diabetologia. 2017;64(12):2741\u201350. https:\/\/doi.org\/10.1007\/s00125-021-05571-8.","journal-title":"Diabetologia"},{"issue":"17","key":"1899_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176275","volume":"21","author":"U Galicia-Garcia","year":"2020","unstructured":"Galicia-Garcia U, Benito-Vicente A, Jebari S, et\u00a0al. Pathophysiology of type 2 diabetes mellitus. IJMS. 2020;21(17):6275. https:\/\/doi.org\/10.3390\/ijms21176275.","journal-title":"IJMS"},{"issue":"6865","key":"1899_CR5","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/414782a","volume":"414","author":"P Zimmet","year":"2001","unstructured":"Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782\u20137. https:\/\/doi.org\/10.1038\/414782a.","journal-title":"Nature"},{"issue":"6","key":"1899_CR6","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.diabet.2020.09.001","volume":"46","author":"B Verg\u00e8s","year":"2020","unstructured":"Verg\u00e8s B. Cardiovascular disease in type 1 diabetes: a review of epidemiological data and underlying mechanisms. Diabetes Metab. 2020;46(6):442\u20139. https:\/\/doi.org\/10.1016\/j.diabet.2020.09.001.","journal-title":"Diabetes Metab"},{"key":"1899_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.117607","volume":"394","author":"J Bor\u00e9n","year":"2024","unstructured":"Bor\u00e9n J, \u00d6\u00f6rni K, Catapano AL. The link between diabetes and cardiovascular disease. Atherosclerosis. 2024;394:117607. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117607.","journal-title":"Atherosclerosis"},{"issue":"40","key":"1899_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035285","volume":"102","author":"Y Lu","year":"2023","unstructured":"Lu Y, Wang W, Liu J, Xie M, Liu Q, Li S. Vascular complications of diabetes: a narrative review. Medicine (Baltimore). 2023;102(40):e35285. https:\/\/doi.org\/10.1097\/MD.0000000000035285.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1899_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/beem.1999.0018","volume":"13","author":"HAA Ibrahim","year":"1999","unstructured":"Ibrahim HAA, Vora JP. Diabetic nephropathy. Best Pract Res Clin Endocrinol Metab. 1999;13(2):239\u201364. https:\/\/doi.org\/10.1053\/beem.1999.0018.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"12","key":"1899_CR10","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/ndt\/15.12.1900","volume":"15","author":"P Ruggenenti","year":"2000","unstructured":"Ruggenenti P, Remuzzi G. Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment? Nephrol Dial Transplant. 2000;15(12):1900\u20132. https:\/\/doi.org\/10.1093\/ndt\/15.12.1900.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1899_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.ackd.2014.03.007","volume":"21","author":"SM Marshall","year":"2014","unstructured":"Marshall SM. Natural history and clinical characteristics of CKD in type 1 and type 2 diabetes mellitus. Adv Chronic Kidney Dis. 2014;21(3):267\u201372. https:\/\/doi.org\/10.1053\/j.ackd.2014.03.007.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"suppl_1","key":"1899_CR12","doi-asserted-by":"publisher","first-page":"s79","DOI":"10.2337\/diacare.27.2007.s79","volume":"27","author":"American Diabetes Association","year":"2004","unstructured":"American Diabetes Association. Nephropathy in diabetes. Diabetes Care. 2004;27(suppl_1):s79\u201383. https:\/\/doi.org\/10.2337\/diacare.27.2007.s79.","journal-title":"Diabetes Care"},{"key":"1899_CR13","unstructured":"Van Dril E. Chronic kidney disease in patients with diabetes. In: PSAP 2023 Book 1 (endocrinology and nephrology). 2023. https:\/\/www.accp.com\/docs\/bookstore\/psap\/p2023b1_sample.pdf."},{"issue":"1","key":"1899_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-12-156","volume":"12","author":"O Schnell","year":"2013","unstructured":"Schnell O, Cappuccio F, Genovese S, Standl E, Valensi P, Ceriello A. Type 1 diabetes and cardiovascular disease. Cardiovasc Diabetol. 2013;12(1):156. https:\/\/doi.org\/10.1186\/1475-2840-12-156.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"1899_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101429","volume":"49","author":"PH Ducluzeau","year":"2023","unstructured":"Ducluzeau PH, Fauchier G, Herbert J, et\u00a0al. Prevalence and incidence of cardiovascular and renal diseases in type 1 compared with type 2 diabetes: a nationwide French observational study of hospitalized patients. Diabetes Metab. 2023;49(3):101429. https:\/\/doi.org\/10.1016\/j.diabet.2023.101429.","journal-title":"Diabetes Metab"},{"issue":"1","key":"1899_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01440-5","volume":"21","author":"E Bosco","year":"2021","unstructured":"Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol. 2021;21(1):241. https:\/\/doi.org\/10.1186\/s12874-021-01440-5.","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"1899_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/m18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et\u00a0al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373. https:\/\/doi.org\/10.7326\/m18-0850.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1899_CR18","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.2337\/diabetes.52.4.1036","volume":"52","author":"ML Caramori","year":"2003","unstructured":"Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients. Diabetes. 2003;52(4):1036\u201340. https:\/\/doi.org\/10.2337\/diabetes.52.4.1036.","journal-title":"Diabetes"},{"issue":"3","key":"1899_CR19","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2337\/dc17-1118","volume":"41","author":"T Costacou","year":"2018","unstructured":"Costacou T, Orchard TJ. Cumulative kidney complication risk by 50 years of type 1 diabetes: the effects of sex, age, and calendar year at onset. Diabetes Care. 2018;41(3):426\u201333. https:\/\/doi.org\/10.2337\/dc17-1118.","journal-title":"Diabetes Care"},{"issue":"5","key":"1899_CR20","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2337\/dc08-1560","volume":"32","author":"LH Ficociello","year":"2009","unstructured":"Ficociello LH, Perkins BA, Roshan B, et\u00a0al. Renal hyperfiltration and the development of microalbuminuria in type 1 diabetes. Diabetes Care. 2009;32(5):889\u201393. https:\/\/doi.org\/10.2337\/dc08-1560.","journal-title":"Diabetes Care"},{"issue":"7","key":"1899_CR21","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2337\/dc06-2534","volume":"30","author":"MS Roy","year":"2007","unstructured":"Roy MS, Affouf M, Roy A. Six-year incidence of proteinuria in type 1 diabetic African Americans. Diabetes Care. 2007;30(7):1807\u201312. https:\/\/doi.org\/10.2337\/dc06-2534.","journal-title":"Diabetes Care"},{"issue":"5","key":"1899_CR22","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1053\/j.ajkd.2007.08.005","volume":"50","author":"T Costacou","year":"2007","unstructured":"Costacou T, Ellis D, Fried L, Orchard TJ. Sequence of progression of albuminuria and decreased GFR in persons with type 1 diabetes: a cohort study. Am J Kidney Dis. 2007;50(5):721\u201332. https:\/\/doi.org\/10.1053\/j.ajkd.2007.08.005.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"1899_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2337\/diacare.22.5.743","volume":"22","author":"R Klein","year":"1999","unstructured":"Klein R, Klein BE, Moss SE, Cruickshanks KJ, Brazy PC. The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care. 1999;22(5):743\u201351. https:\/\/doi.org\/10.2337\/diacare.22.5.743.","journal-title":"Diabetes Care"},{"issue":"4","key":"1899_CR24","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1681\/asn.2006080872","volume":"18","author":"BA Perkins","year":"2007","unstructured":"Perkins BA, Ficociello LH, Ostrander BE, et\u00a0al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol. 2007;18(4):1353\u201361. https:\/\/doi.org\/10.1681\/asn.2006080872.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"1899_CR25","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.2337\/dc18-0277","volume":"41","author":"B Warren","year":"2018","unstructured":"Warren B, Rebholz CM, Sang Y, et\u00a0al. Diabetes and trajectories of estimated glomerular filtration rate: a prospective cohort analysis of the atherosclerosis risk in communities study. Diabetes Care. 2018;41(8):1646\u201353. https:\/\/doi.org\/10.2337\/dc18-0277.","journal-title":"Diabetes Care"},{"issue":"8","key":"1899_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108233","volume":"36","author":"J Guo","year":"2022","unstructured":"Guo J, Costacou T, Orchard TJ. Long term risk of heart failure in individuals with childhood-onset type 1 diabetes. J Diabetes Complications. 2022;36(8):108233. https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108233.","journal-title":"J Diabetes Complications"},{"issue":"17","key":"1899_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.17.1917","volume":"164","author":"BEK Klein","year":"2004","unstructured":"Klein BEK, Klein R, McBride PE, et\u00a0al. Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. Arch Intern Med. 2004;164(17):1917. https:\/\/doi.org\/10.1001\/archinte.164.17.1917.","journal-title":"Arch Intern Med"},{"issue":"4","key":"1899_CR28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/s0272-6386(97)90344-9","volume":"29","author":"CL Manske","year":"1997","unstructured":"Manske CL, Wilson RF, Wang Y, Thomas W. Atherosclerotic vascular complications in diabetic transplant candidates. Am J Kidney Dis. 1997;29(4):601\u20137. https:\/\/doi.org\/10.1016\/s0272-6386(97)90344-9.","journal-title":"Am J Kidney Dis"},{"key":"1899_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ahj.2016.08.002","volume":"181","author":"FL Mondesir","year":"2016","unstructured":"Mondesir FL, Brown TM, Muntner P, et\u00a0al. Diabetes, diabetes severity, and coronary heart disease risk equivalence: Reasons for Geographic and Racial Differences in Stroke (REGARDS). Am Heart J. 2016;181:43\u201351. https:\/\/doi.org\/10.1016\/j.ahj.2016.08.002.","journal-title":"Am Heart J"},{"issue":"12","key":"1899_CR30","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/j.mayocp.2022.05.021","volume":"97","author":"FL Norby","year":"2022","unstructured":"Norby FL, Reinier K, Uy-Evanado A, et\u00a0al. Sudden cardiac death in patients with type 1 versus type 2 diabetes. Mayo Clin Proc. 2022;97(12):2271\u201381. https:\/\/doi.org\/10.1016\/j.mayocp.2022.05.021.","journal-title":"Mayo Clin Proc"},{"issue":"15","key":"1899_CR31","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.2165\/00019053-200422150-00005","volume":"22","author":"FB Dong","year":"2004","unstructured":"Dong FB, Sorensen SW, Manninen DL, et\u00a0al. Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus. Pharmacoeconomics. 2004;22(15):1015\u201327. https:\/\/doi.org\/10.2165\/00019053-200422150-00005.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1899_CR32","first-page":"310","volume":"11","author":"VJ Willey","year":"2018","unstructured":"Willey VJ, Kong S, Wu B, et\u00a0al. Estimating the real-world cost of diabetes mellitus in the United States during an 8-year period using 2 cost methodologies. Am Health Drug Benef. 2018;11(6):310\u20138.","journal-title":"Am Health Drug Benef"},{"key":"1899_CR33","doi-asserted-by":"publisher","unstructured":"Yang W, Cintina I, Hoerger T, et\u00a0al. Estimating costs of diabetes complications in people <65 years in the U.S. using panel data. J Diabetes Complic. 2020;34(12):107735. https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107735","DOI":"10.1016\/j.jdiacomp.2020.107735"},{"issue":"2","key":"1899_CR34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40258-014-0086-9","volume":"12","author":"J Yeaw","year":"2014","unstructured":"Yeaw J, Halinan S, Hines D, et\u00a0al. Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting. Appl Health Econ Health Policy. 2014;12(2):219\u201330. https:\/\/doi.org\/10.1007\/s40258-014-0086-9.","journal-title":"Appl Health Econ Health Policy"},{"key":"1899_CR35","unstructured":"FDA. FARXIGA (dapagliflozin). Published online May 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/202293s026lbl.pdf."},{"key":"1899_CR36","unstructured":"FDA. Diabetes mellitus: efficacy endpoints for clinical trials investigating antidiabetic drugs and biological products. Published online May 2023. https:\/\/www.fda.gov\/media\/168475\/download."},{"key":"1899_CR37","unstructured":"FDA. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. March 16, 2022. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious."},{"key":"1899_CR38","unstructured":"FDA. INPEFA (Sotagliflozin). Published online May 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216203s000lbl.pdf."},{"key":"1899_CR39","unstructured":"FDA. Table of surrogate endpoints that were the basis of drug approval or licensure. December 17, 2024. https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure."},{"issue":"10","key":"1899_CR40","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.2337\/dc19-0349","volume":"42","author":"D Vistisen","year":"2019","unstructured":"Vistisen D, Andersen GS, Hulman A, Persson F, Rossing P, J\u00f8rgensen ME. Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function\u2014even without albuminuria. Diabetes Care. 2019;42(10):1886\u201394. https:\/\/doi.org\/10.2337\/dc19-0349.","journal-title":"Diabetes Care"},{"issue":"24","key":"1899_CR41","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et\u00a0al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2110956.","journal-title":"N Engl J Med"},{"issue":"23","key":"1899_CR42","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et\u00a0al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"issue":"2","key":"1899_CR43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et\u00a0al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"15","key":"1899_CR44","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et\u00a0al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"24","key":"1899_CR45","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et\u00a0al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"2","key":"1899_CR46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"issue":"4","key":"1899_CR47","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5897\/JPAP2013.0001","volume":"4","author":"O Ozougwu","year":"2013","unstructured":"Ozougwu O. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. J Physiol Pathophysiol. 2013;4(4):46\u201357. https:\/\/doi.org\/10.5897\/JPAP2013.0001.","journal-title":"J Physiol Pathophysiol"},{"issue":"10085","key":"1899_CR48","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","volume":"389","author":"S Chatterjee","year":"2017","unstructured":"Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(17)30058-2.","journal-title":"Lancet"},{"issue":"2","key":"1899_CR49","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1530\/EJE-18-0515","volume":"180","author":"C Nederstigt","year":"2019","unstructured":"Nederstigt C, Uitbeijerse BS, Janssen LGM, Corssmit EPM, De Koning EJP, Dekkers OM. Associated auto-immune disease in type 1 diabetes patients: a systematic review and meta-analysis. Eur J Endocrinol. 2019;180(2):135\u201344. https:\/\/doi.org\/10.1530\/EJE-18-0515.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"1899_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016587","volume":"7","author":"SF Farsani","year":"2017","unstructured":"Farsani SF, Brodovicz K, Soleymanlou N, Marquard J, Wissinger E, Maiese BA. Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review. BMJ Open. 2017;7(7):e016587. https:\/\/doi.org\/10.1136\/bmjopen-2017-016587.","journal-title":"BMJ Open"},{"issue":"3","key":"1899_CR51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2337\/diaclin.24.3.115","volume":"24","author":"VJ Briscoe","year":"2006","unstructured":"Briscoe VJ, Davis SN. Hypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology,and management. Clin Diabetes. 2006;24(3):115\u201321. https:\/\/doi.org\/10.2337\/diaclin.24.3.115.","journal-title":"Clin Diabetes"},{"key":"1899_CR52","unstructured":"deBoer I. Trial of semaglutide for diabetic kidney disease in type 1 diabetes. clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT05822609. Accessed March 10, 2026."},{"key":"1899_CR53","unstructured":"Doria A. Sotagliflozin to slow kidney function decline in persons with type 1 diabetes and diabetic kidney disease. clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT06217302. Accessed 10 Mar 2026."},{"issue":"10","key":"1899_CR54","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa2512854","volume":"394","author":"HJL Heerspink","year":"2026","unstructured":"Heerspink HJL, Birkenfeld AL, Cherney DZI, et\u00a0al. Finerenone in type 1 diabetes and chronic kidney disease. N Engl J Med. 2026;394(10):947\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2512854.","journal-title":"N Engl J Med"},{"issue":"4","key":"1899_CR55","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1111\/j.1523-1755.2005.00556.x","volume":"68","author":"P Rossing","year":"2005","unstructured":"Rossing P, Hougaard P, Parving HH. Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study. Kidney Int. 2005;68(4):1446\u201350. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00556.x.","journal-title":"Kidney Int"},{"issue":"10","key":"1899_CR56","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1093\/ndt\/gfv121","volume":"30","author":"P Bjornstad","year":"2015","unstructured":"Bjornstad P, Cherney DZ, Snell-Bergeon JK, et\u00a0al. Rapid GFR decline is associated with renal hyperfiltration and impaired GFR in adults with type 1 diabetes. Nephrol Dial Transplant. 2015;30(10):1706\u201311. https:\/\/doi.org\/10.1093\/ndt\/gfv121.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"1899_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2024.108864","volume":"38","author":"K Favel","year":"2024","unstructured":"Favel K, Bone JN, Elliott T, Panagiotopoulos C, Mammen C. Classification of longitudinal estimated glomerular filtration rate trajectories in Canadian adults with type 1 diabetes. J Diabetes Complications. 2024;38(11):108864. https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108864.","journal-title":"J Diabetes Complications"},{"issue":"3","key":"1899_CR58","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2337\/dc21-1883","volume":"45","author":"BA Perkins","year":"2022","unstructured":"Perkins BA, Bebu I, Gao X, et\u00a0al. Early trajectory of estimated glomerular filtration rate and long-term advanced kidney and cardiovascular complications in type 1 diabetes. Diabetes Care. 2022;45(3):585\u201393. https:\/\/doi.org\/10.2337\/dc21-1883.","journal-title":"Diabetes Care"},{"issue":"8","key":"1899_CR59","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.8.1093","volume":"160","author":"CT Valmadrid","year":"2000","unstructured":"Valmadrid CT, Klein R, Moss SE, Klein BEK. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160(8):1093. https:\/\/doi.org\/10.1001\/archinte.160.8.1093.","journal-title":"Arch Intern Med"},{"issue":"11","key":"1899_CR60","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.2215\/cjn.02870316","volume":"11","author":"IH De Boer","year":"2016","unstructured":"De Boer IH, Gao X, Cleary PA, et\u00a0al. Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT\/EDIC study. CJASN. 2016;11(11):1969\u201377. https:\/\/doi.org\/10.2215\/cjn.02870316.","journal-title":"CJASN"},{"issue":"1","key":"1899_CR61","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1932296815596174","volume":"10","author":"D Vestberg","year":"2016","unstructured":"Vestberg D, Rosengren A, Olsson M, et\u00a0al. Decreased eGFR as a risk factor for heart failure in 13 781 individuals with type 1 diabetes. J Diabetes Sci Technol. 2016;10(1):131\u20136. https:\/\/doi.org\/10.1177\/1932296815596174.","journal-title":"J Diabetes Sci Technol"},{"issue":"7","key":"1899_CR62","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s001250050988","volume":"41","author":"J Tuomilehto","year":"1998","unstructured":"Tuomilehto J, Borch-Johnsen K, Molarius A, et\u00a0al. Incidence of cardiovascular disease in type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia. 1998;41(7):784\u201390. https:\/\/doi.org\/10.1007\/s001250050988.","journal-title":"Diabetologia"},{"key":"1899_CR63","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jaut.2016.03.008","volume":"71","author":"MR Ehlers","year":"2016","unstructured":"Ehlers MR. Strategies for clinical trials in type 1 diabetes. J Autoimmun. 2016;71:88\u201396. https:\/\/doi.org\/10.1016\/j.jaut.2016.03.008.","journal-title":"J Autoimmun"},{"issue":"21","key":"1899_CR64","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/nejmoa1408214","volume":"371","author":"M Lind","year":"2014","unstructured":"Lind M, Svensson AM, Kosiborod M, et\u00a0al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371(21):1972\u201382. https:\/\/doi.org\/10.1056\/nejmoa1408214.","journal-title":"N Engl J Med"},{"issue":"6","key":"1899_CR65","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s13300-025-01735-6","volume":"16","author":"L Starr","year":"2025","unstructured":"Starr L, Dutta S, Danne T, Karpen SR, Hutton C, Kowalski A. The urgent need for breakthrough therapies and a world without type 1 diabetes. Diabetes Ther. 2025;16(6):1063\u201376. https:\/\/doi.org\/10.1007\/s13300-025-01735-6.","journal-title":"Diabetes Ther"},{"key":"1899_CR66","unstructured":"Lucier J, Mathias P. Type 1 diabetes. Published online January 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507713\/."},{"issue":"11","key":"1899_CR67","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.2337\/dci21-0043","volume":"44","author":"RIG Holt","year":"2021","unstructured":"Holt RIG, DeVries JH, Hess-Fischl A, et\u00a0al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021;44(11):2589\u2013625. https:\/\/doi.org\/10.2337\/dci21-0043.","journal-title":"Diabetes Care"},{"issue":"11","key":"1899_CR68","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/s2213-8587(17)30315-7","volume":"5","author":"JR Petrie","year":"2017","unstructured":"Petrie JR. SGLT2 inhibitors in type 1 diabetes: knocked down, but up again? Lancet Diabetes Endocrinol. 2017;5(11):841\u20133. https:\/\/doi.org\/10.1016\/s2213-8587(17)30315-7.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1899_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110908","volume":"204","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Birkenfeld AL, Cherney DZI, et\u00a0al. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: the FINE-ONE trial. Diabetes Res Clin Pract. 2023;204:110908. https:\/\/doi.org\/10.1016\/j.diabres.2023.110908.","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"1899_CR70","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1080\/13543784.2022.2159806","volume":"31","author":"JG Timmons","year":"2022","unstructured":"Timmons JG, Littlejohn L, Boyle JG, Petrie JR. Recent developments in adjunct therapies for type 1 diabetes. Expert Opin Investig Drugs. 2022;31(12):1311\u201320. https:\/\/doi.org\/10.1080\/13543784.2022.2159806.","journal-title":"Expert Opin Investig Drugs"},{"key":"1899_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1506652","author":"Y Lei","year":"2025","unstructured":"Lei Y, Yao S, Wang Z, Tu Q, Yuan Z, Jiang Q. Safety and efficacy of adjuvant sotagliflozin therapy in patients with T1D\u2014an update and systematic review and meta-analysis. Front Endocrinol. 2025. https:\/\/doi.org\/10.3389\/fendo.2025.1506652.","journal-title":"Front Endocrinol"},{"issue":"2","key":"1899_CR72","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/dom.14248","volume":"23","author":"M Phillip","year":"2021","unstructured":"Phillip M, Mathieu C, Lind M, et\u00a0al. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies. Diabetes Obes Metab. 2021;23(2):549\u201360. https:\/\/doi.org\/10.1111\/dom.14248.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1899_CR73","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.2337\/dc18-1749","volume":"41","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Marquard J, Laffel LM, et\u00a0al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care. 2018;41(12):2560\u20139. https:\/\/doi.org\/10.2337\/dc18-1749.","journal-title":"Diabetes Care"},{"issue":"4","key":"1899_CR74","doi-asserted-by":"publisher","first-page":"380","DOI":"10.34172\/hpp.42486","volume":"14","author":"M Najafipour","year":"2024","unstructured":"Najafipour M, Najafipour F, Ostadrahimi A, et\u00a0al. The effects of empagliflozin in patients with type 1 diabetes: results of a 12-week, double-blind, randomized, placebo-controlled clinical trial. Health Promot Perspect. 2024;14(4):380\u20137. https:\/\/doi.org\/10.34172\/hpp.42486.","journal-title":"Health Promot Perspect"},{"issue":"10","key":"1899_CR75","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/dom.12494","volume":"17","author":"TR Pieber","year":"2015","unstructured":"Pieber TR, Famulla S, Eilbracht J, et\u00a0al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4\u2010week, randomized, placebo\u2010controlled trial (EASE\u20101). Diabetes Obes Metab. 2015;17(10):928\u201335. https:\/\/doi.org\/10.1111\/dom.12494.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1899_CR76","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2174\/1573399815666190614141918","volume":"16","author":"P Dimitrios","year":"2020","unstructured":"Dimitrios P, Michael D, Vasilios K, et\u00a0al. Liraglutide as adjunct to insulin treatment in patients with type 1 diabetes: a systematic review and meta-analysis. CDR. 2020;16(4):313\u201326. https:\/\/doi.org\/10.2174\/1573399815666190614141918.","journal-title":"CDR"},{"issue":"4","key":"1899_CR77","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/s2213-8587(20)30030-9","volume":"8","author":"NJ Johansen","year":"2020","unstructured":"Johansen NJ, Dejgaard TF, Lund A, et\u00a0al. Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2020;8(4):313\u201324. https:\/\/doi.org\/10.1016\/s2213-8587(20)30030-9.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01899-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01899-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01899-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T20:03:13Z","timestamp":1788638593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01899-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":77,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1899"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01899-9","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Navdeep Tangri has received research support and honoraria from Bayer US. Arvind Katta, Carolina Aldworth, Jon Mares, Zihe Zheng, and Mauricio Ferri are employees of Bayer US or were employed by Bayer US at the time of this research. Favian Co, Reid Whitlock, and Nicole Askin have no conflicts of interest to declare. There are no other relationships or activities that could appear to have influenced the submitted work.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}